Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of...

Full description

Bibliographic Details
Main Authors: Marta Campos, Isabel Candelária, Nickolas Papanikolaou, Adélia Simão, Carlos Ferreira, Georgios C. Manikis, Filipe Caseiro-Alves
Format: Article
Language:English
Published: Karger Publishers 2019-02-01
Series:GE: Portuguese Journal of Gastroenterology
Subjects:
Hepatocellular carcinoma
Sorafenib
Angiogenesis
Magnetic resonance imaging perfusion
ktrans
Tumor markers
Online Access:https://www.karger.com/Article/FullText/493351

Internet

https://www.karger.com/Article/FullText/493351

Similar Items